Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's PEG Ratio or its related term are showing as below:
NSE:MADHAVBAUG'
s PEG Ratio Range Over the Past 10 Years
Min: 0.59 Med: 1.55 Max: 4.81
Current: 1.2
During the past 8 years, Vaidyane Ayurved Laboratories's highest PEG Ratio was 4.81. The lowest was 0.59. And the median was 1.55.
NSE:MADHAVBAUG's PEG Ratio is ranked better than 62.36% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs NSE:MADHAVBAUG: 1.20
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Vaidyane Ayurved Laboratories PEG Ratio Related Terms
Vaidyane Ayurved Laboratories PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a PEG Ratio of 1.20 as of Jul. 18, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 23% below median its historical median of 1.55. Over the past decade, Vaidyane Ayurved Laboratories' PEG Ratio has ranged from 0.59 to 4.81. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #131 out of 348 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Vaidyane Ayurved Laboratories' PEG Ratio too high?
Vaidyane Ayurved Laboratories' current PEG Ratio of 1.20 is 23% below median its 10-year median of 1.55. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 4.81. The Drug Manufacturers industry median PEG Ratio is 1.72. Vaidyane Ayurved Laboratories' value of 1.20 is 30% below this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #131 out of 348 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #131 out of 348 companies for PEG Ratio. This puts Vaidyane Ayurved Laboratories in the upper half of its industry. The industry median PEG Ratio is 1.72. Vaidyane Ayurved Laboratories' value of 1.20 is 30% below this benchmark. Historically, Vaidyane Ayurved Laboratories' own PEG Ratio has ranged from 0.59 to 4.81 over the past decade. While the company's 10-year median is 1.55 vs. the industry median of 1.72, Vaidyane Ayurved Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current PEG Ratio of 1.20 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current PEG Ratio is 1.20, which is 23% below median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.14, compared to a current price of ₹204.85 — trading 10.2% below its estimated fair value. The current PEG Ratio is 1.20, which is 23% below median its 10-year median of 1.55 and 30% below the Drug Manufacturers industry median of 1.72. Vaidyane Ayurved Laboratories' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current PEG Ratio is 1.20 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹204.85 is trading 10.2% below its estimated GF Value™ of ₹228.14.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
PEG Ratio: 1.20 (23% below median its 10-year median of 1.55)
GF Value™: ₹228.14 vs. price of ₹204.85 (10.2% below fair value)
Industry Position: 30% below the Drug Manufacturers median (#131 of 348)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
78GF Score
Get the complete analysis for NSE:MADHAVBAUG
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
